Khan Ishrat Jahan, M. Siddiqui, Mohammed Aleemuddin Quamri, Hamiduddin Hamiduddin, Siddiqui Aafreen
{"title":"Efficacy of Kabab Chini (Piper cubeba Linn) in Chronic Kidney Disease: A Randomized Controlled Clinical Trial","authors":"Khan Ishrat Jahan, M. Siddiqui, Mohammed Aleemuddin Quamri, Hamiduddin Hamiduddin, Siddiqui Aafreen","doi":"10.34172/ajmb.2023.2376","DOIUrl":null,"url":null,"abstract":"Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients cannot afford the cost of treatment for CKD, over 1 million people worldwide alive on dialysis or with a functioning graft. It is the need of the time to find alternate treatment to control CKD. Hence this study aims to evaluate clinically the efficacy of Kabab Chini (Piper cubeba) in CKD stage 1-3 and also to compare the effectiveness of the marketed drug NEERI KFT® scientifically. Objectives: To evaluate the efficacy of Kabab Chini (Piper cubeba) in chronic kidney disease (CKD) stage 1-3 patients. Methods: In this open-labeled randomized controlled clinical trial, 30 participants, randomly allocated to two groups, received 4 g of either sufoof (powder) of Kabab Chini in a divided dose thrice a day (Test group, n=15) or 10 mL of Syrup NEERI-KFT three times a day (Control group, n=15) for 42 days. The objective parameters were serum creatinine, blood urea (BU), estimated glomerular filtration rate (eGFR), and urine routine and microscopy, whereas subjective parameters were anorexia, easy fatigability, and edema. Objective and subjective parameters were assessed at weekly follow-ups, and safety parameters were assessed at baseline and after 42 days. Results: Intragroup data suggest significant improvements in anorexia, easy fatigability, and eGFR in both groups (P=0.001), whereas the intragroup serum creatinine value was significantly reduced in the test (P=0.028) and control (P=0.256) groups. No significant improvement in edema and albumin was observed in both groups (P>0.05). The test drug was found to be tolerable with no adverse effects. Conclusion: The results of the present study revealed that Kabab Chini is effective in reducing serum creatinine, eGFR, anorexia, and easy fatigability moderately superior to Syrup NEERI-KFT® with respect to efficacy without any adverse effect and accepted alternate hypothesis.","PeriodicalId":165658,"journal":{"name":"Avicenna Journal of Medical Biochemistry","volume":"44 3","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Medical Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ajmb.2023.2376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic Kidney Disease (CKD) is a major public health problem with a global prevalence of approximately 13% with the majority stage 3 and is a global threat to health in general and for developing countries in particular, because therapy is expensive and life-long. In India 90% patients cannot afford the cost of treatment for CKD, over 1 million people worldwide alive on dialysis or with a functioning graft. It is the need of the time to find alternate treatment to control CKD. Hence this study aims to evaluate clinically the efficacy of Kabab Chini (Piper cubeba) in CKD stage 1-3 and also to compare the effectiveness of the marketed drug NEERI KFT® scientifically. Objectives: To evaluate the efficacy of Kabab Chini (Piper cubeba) in chronic kidney disease (CKD) stage 1-3 patients. Methods: In this open-labeled randomized controlled clinical trial, 30 participants, randomly allocated to two groups, received 4 g of either sufoof (powder) of Kabab Chini in a divided dose thrice a day (Test group, n=15) or 10 mL of Syrup NEERI-KFT three times a day (Control group, n=15) for 42 days. The objective parameters were serum creatinine, blood urea (BU), estimated glomerular filtration rate (eGFR), and urine routine and microscopy, whereas subjective parameters were anorexia, easy fatigability, and edema. Objective and subjective parameters were assessed at weekly follow-ups, and safety parameters were assessed at baseline and after 42 days. Results: Intragroup data suggest significant improvements in anorexia, easy fatigability, and eGFR in both groups (P=0.001), whereas the intragroup serum creatinine value was significantly reduced in the test (P=0.028) and control (P=0.256) groups. No significant improvement in edema and albumin was observed in both groups (P>0.05). The test drug was found to be tolerable with no adverse effects. Conclusion: The results of the present study revealed that Kabab Chini is effective in reducing serum creatinine, eGFR, anorexia, and easy fatigability moderately superior to Syrup NEERI-KFT® with respect to efficacy without any adverse effect and accepted alternate hypothesis.
背景:慢性肾脏疾病(CKD)是一个主要的公共卫生问题,全球患病率约为13%,其中大多数为3期,是对全球健康的威胁,特别是对发展中国家,因为治疗费用昂贵且终身。在印度,90%的患者负担不起慢性肾病的治疗费用,全世界有超过100万人依靠透析或移植器官存活。需要时间来寻找控制CKD的替代治疗方法。因此,本研究旨在评估Kabab Chini (Piper cubeba)在CKD 1-3期的临床疗效,并科学地比较已上市药物NEERI KFT®的疗效。目的:评价中药卡巴布治疗慢性肾脏病(CKD) 1-3期患者的疗效。方法:在这项开放标记的随机对照临床试验中,30名参与者被随机分为两组,每天3次(试验组,n=15)或10 mL NEERI-KFT糖浆(对照组,n=15),每天3次,连续42天。客观指标为血清肌酐、血尿素(BU)、肾小球滤过率(eGFR)、尿常规和镜检,主观指标为厌食、易疲劳和水肿。在每周随访时评估客观和主观参数,在基线和42天后评估安全性参数。结果:组内数据显示,两组的厌食症、易疲劳和eGFR均有显著改善(P=0.001),而试验组(P=0.028)和对照组(P=0.256)的组内血清肌酐值均显著降低。两组患者水肿、白蛋白均无明显改善(P>0.05)。试验药物被发现是可耐受的,没有副作用。结论:本研究结果显示,Kabab Chini在降低血清肌酐、eGFR、厌食症和易疲劳方面具有一定的疗效,且无任何不良反应,并接受了另一种假设。